Bucks County specialty pharmaceutical company Optinose first started exploring mergers and licensing deals in early 2022.

Yardley-based Optinose, which put itself up for auction three years ago attracting multiple suitors, has secured a potential ...

XHANCE is an innovative, drug-device combination product approved for the treatment of CRS with or without nasal polyps. By optimally targeting the site of inflammation with a proven ...

Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

Xhance is an innovative drug-device therapy for chronic rhinosinusitis (CRS), with or without nasal polyps. Utilizing its proprietary Exhalation Delivery System, it delivers a corticosteroid ...